Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14616502 | 0.84 | IRAK4 (0.35) | USP2LMNAMAPT | |
| SCHEMBL4226883 | 0.73 | DRD2 (0.36) | DRD2DRD4DRD3HRH3 | |
| SCHEMBL3980581 | 0.73 | POLB (0.38) | DRD2DRD4DRD3HRH3MAPT | |
| SCHEMBL2715907 | 0.73 | DRD2 (0.36) | DRD2DRD4DRD3HRH3 | |
| SCHEMBL4283522 | 0.73 | DRD2 (0.36) | DRD2DRD4DRD3HRH3 | |
| SCHEMBL15077175 | 0.72 | CCNT1 (0.33) | DRD2DRD4DRD3HRH3 | |
| SCHEMBL21580175 | 0.72 | DRD2 (0.33) | DRD2DRD4DRD3HRH3 | |
| SCHEMBL13564548 | 0.72 | DRD2 (0.46) | DRD2DRD4DRD3HRH3 | |
| SCHEMBL17526022 | 0.71 | CCR1 (0.33) | — | |
| Hydrochloric Acid SCHEMBL31352065 | 0.71 | POLB (0.36) | DRD2DRD4DRD3HRH3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11999740-B2 | Fused pyrazine derivatives as A2A / A2B inhibitors | INCYTE CORPORATION (US) | 2024-06-04 | — | — | US | claimed |
| US-20220135570-A1 | FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2022-05-05 | — | — | US | claimed |
| US-20200031835-A1 | FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2020-01-30 | — | — | US | claimed |
| US-12577243-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-17 | — | — | US | disclosed |
| US-12263171-B2 | 7-, 8-, and 10-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use | MERCK SHARP & DOHME LLC (US) | 2025-04-01 | — | — | US | disclosed |
| US-20240327410-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2024-10-03 | — | — | US | disclosed |
| WO-2024130344-A1 | TRANSIENT RECEPTOR POTENTIAL VANILLOID 6 INHIBITORS | UNIQUEST PTY LIMITED (AU) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024130342-A1 | TRANSIENT RECEPTOR POTENTIAL VANILLOID 6 INHIBITORS | UNIQUEST PTY LIMITED (AU) | 2024-06-27 | — | — | WO | disclosed |
| US-11999740-B2 | Fused pyrazine derivatives as A2A / A2B inhibitors | INCYTE CORPORATION (US) | 2024-06-04 | — | — | US | disclosed |
| US-11993601-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV | 2024-05-28 | — | — | US | disclosed |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | SCHRÖDINGER, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20120258950-A1 | PYRROLO[2,3-d]PYRIMIDINE TROPOMYSIN-RELATED KINASE INHIBITORS | PFIZER LIMITED (GB) | 2012-10-11 | — | — | US | disclosed |
| US-20110207737-A1 | SUBSTITUTED BICYCLIC AMINES FOR THE TREATMENT OF DIABETES | MERCK SHARP & DOHME CORP | 2011-08-25 | — | — | US | disclosed |
| US-20110207737-A1 | SUBSTITUTED BICYCLIC AMINES FOR THE TREATMENT OF DIABETES | MERCK SHARP & DOHME CORP | 2011-08-25 | — | — | US | disclosed |
| WO-2010056717-A1 | SUBSTITUTED BICYCLIC AMINES FOR THE TREATMENT OF DIABETES | MERCK SHARP & DOHME CORP. (US) | 2010-05-20 | — | — | WO | disclosed |
| WO-2009152027-A1 | 5,7-DIHYDRO-6H-PYRROLO[2,3-D]PYRIMIDIN-6-ONE DERIVATIVES FOR MARK INHIBITION | MERCK & CO., INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| EP-1878734-A1 | NOVEL LACTAM COMPOUND | Ajinomoto Co., Inc. (JP) | 2008-01-16 | — | — | EP | disclosed |
| EP-0164113-B1 | 3-PYRAZOLO(1,5-A)PYRIDINIUM CEPHEM COMPOUNDS, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1990-05-16 | — | — | EP | disclosed |
| US-4665065-A | 3-pyrazolo(1,5-aαpyridinium cephem compounds | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1987-05-12 | — | — | US | disclosed |
| EP-0164113-A2 | 3-pyrazolo(1,5-a)pyridinium cephem compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1985-12-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135570-A1 | FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS | ADORA2A, ADORA2B, ADORA1 | DRD2 1202/4885DRD4 3359/4885DRD3 2304/4885 |
| US-20110207737-A1 | SUBSTITUTED BICYCLIC AMINES FOR THE TREATMENT OF DIABETES | SSTR5, TAAR5, MC5R | DRD2 216/4885DRD4 703/4885DRD3 447/4885 |
| US-12577243-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, FAAH | DRD2 497/4885DRD4 1036/4885DRD3 295/4885 |
| US-20200031835-A1 | FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS | ADORA2A, ADORA2B, ADORA1 | DRD2 1202/4885DRD4 3359/4885DRD3 2304/4885 |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | DRD2 4869/4885DRD4 4878/4885DRD3 4827/4885 |
| US-11993601-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | DRD2 559/4885DRD4 1614/4885DRD3 803/4885 |
| US-11999740-B2 | Fused pyrazine derivatives as A2A / A2B inhibitors | ADORA2A, ADORA2B, ADORA1 | DRD2 1202/4885DRD4 3359/4885DRD3 2304/4885 |
| US-20120258950-A1 | PYRROLO[2,3-d]PYRIMIDINE TROPOMYSIN-RELATED KINASE INHIBITORS | DMPK, DTYMK, MUSK | DRD2 3543/4885DRD4 4390/4885DRD3 3547/4885 |
| US-20240327410-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | DRD2 559/4885DRD4 1614/4885DRD3 803/4885 |
| US-12263171-B2 | 7-, 8-, and 10-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use | ADORA2A, ADORA2B, ADORA3 | DRD2 367/4885DRD4 1009/4885DRD3 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.